Neurotrope hammered after Alzheimer's readout

Neurotrope Inc. (NASDAQ:NTRP) plummeted $11.84 (63%) to $6.97 after announcing results of a Phase II study of Bryostatin-1 to treat Alzheimer's disease. On the primary endpoint, which measured improvements in Severe Impairment Battery (SIB) scores vs. placebo, a 20 μg dose of the therapy failed to meet a prespecified one-tailed significance threshold of p<0.1 in the trial's modified intent to treat (mITT) population (increase of 1.2 points vs. decrease of 0.8 points, one-tailed p value of <0.134).

In the study's completer population, the 20 μg dose did meet the significance threshold for the primary endpoint. The dose improved SIB scores by 1.5 points vs. a 1.1 point decrease in placebo-treated patients after 13 weeks (p<0.07, one-tailed)...